Patent · US Active

CMP-dependent sialidase activity

US11788108B2 · kind B2 · utility

0Cited by

13References

7Claims

0Family size

Assignee

Roche Diagnostics Operations, Inc. · US

Inventors

Harald Sobek · Penzberg, DE
Michael Greif · Penzberg, DE
Marco Thomann · Beuerberg, DE
Sebastian Malik · Antdorf, DE

Key dates

Filing date	Jun 23, 2021
Grant date	Oct 17, 2023
Priority date	—
Expiry date	Jun 23, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/41
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

The properties of certain glycosyltransferase variants having N-terminal truncation deletions or internal deletions are disclosed. Particularly, mutants that exhibit α-2,6-sialyltransferase enzymatic activity in the presence of CMP-activated sialic acid as co-substrate, and in the presence of a suitable acceptor site, are disclosed. A fundamental finding documented in the present disclosure is that enzymes are not only capable of catalyzing transfer of a sialidyl moiety but they are also capable of catalyzing hydrolytic cleavage of terminally bound sialic acid from a glycan.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.